Citius Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Citius Pharmaceuticals sono diminuiti a un tasso annuo medio di -19.6%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso annuo di 0.1%.

Informazioni chiave

-19.6%

Tasso di crescita degli utili

31.0%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	6.0%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-44.4%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28

Citius: Halt For Superiority On The Horizon

Jun 15

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

May 15

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results

Apr 26

Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Dec 18

Ripartizione dei ricavi e delle spese

Come Citius Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqCM:CTXR Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	-40	29	12
31 Mar 24	-37	26	13
31 Dec 23	-39	25	14
30 Sep 23	-34	22	15
30 Jun 23	-31	18	16
31 Mar 23	-31	17	17
31 Dec 22	-28	16	16
30 Sep 22	-34	16	18
30 Jun 22	-31	15	16
31 Mar 22	-29	15	13
31 Dec 21	-26	13	12
30 Sep 21	-25	11	12
30 Jun 21	-24	11	11
31 Mar 21	-21	9	12
31 Dec 20	-21	9	12
30 Sep 20	-18	9	9
30 Jun 20	-17	8	9
31 Mar 20	-17	8	9
31 Dec 19	-16	7	9
30 Sep 19	-16	7	9
30 Jun 19	-15	7	8
31 Mar 19	-12	7	6
31 Dec 18	-13	6	8
30 Sep 18	-13	7	7
30 Jun 18	-13	7	5
31 Mar 18	-13	8	5
31 Dec 17	-11	8	2
30 Sep 17	-10	7	3
30 Jun 17	-10	7	4
31 Mar 17	-11	6	5
31 Dec 16	-9	5	4
30 Sep 16	-8	5	3
30 Jun 16	-7	3	2
31 Mar 16	-4	2	2
31 Dec 15	-3	1	2
30 Sep 15	-3	1	2
30 Jun 15	-3	2	1
31 Mar 15	-2	1	1
31 Dec 14	-2	1	0
30 Sep 14	-1	1	0
30 Jun 14	-1	0	0
31 Mar 14	-1	0	0

Guadagni di qualità: CTXR al momento non è redditizia.

Margine di profitto in crescita: CTXR al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: CTXR non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 19.6% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di CTXR nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: CTXR non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 54.6% ).

Rendimento del capitale proprio

ROE elevato: CTXR ha un Return on Equity negativo ( -44.38% ), in quanto al momento non è redditizio.

Citius Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New major risk - Financial position

New minor risk - Profitability

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

New minor risk - Share price stability

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Price target decreased by 21% to US$3.17

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Consensus EPS estimates fall by 24%

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Forecast breakeven date pushed back to 2025

Price target increased by 25% to US$5.00

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Price target decreased to US$3.60

Insufficient new directors

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals GAAP EPS of -$0.06

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Price target increased to US$4.00

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Critical Care Biopharma - Citius Pharmaceuticals

Forecast breakeven date pushed back to 2024

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Citius: 2022 Is A Year Of Catalysts

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Forecast breakeven date moved forward to 2023

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million.

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

Citius: Halt For Superiority On The Horizon

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc. Reports Strong Clinical Community Engagement During Mino-Lok Phase 3 Trial-Related Webinar

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $76.500002 million.

New 90-day high: US$1.69

Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies At the Virtual Investor Conferences Small and Microcap Showcase on February 4

Citius Pharmaceuticals, Inc. announced that it has received $20.000012 million in funding

Citius Pharmaceuticals, Inc. announced that it expects to receive $20.000012 million in funding